Wire · operational-macro
VIR-5500 Receives FDA Fast Track Designation in mCRPC
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 10 October 2026 · Fusion42 review
The FDA granted fast track designation to VIR-5500, a PSMA-targeted T-cell engager, for late-line metastatic castration-resistant prostate cancer (mCRPC), accelerating its development. VIR-5500 is currently in phase 1 trials, showing promising safety and efficacy, with phase 3 trials planned for 2027.
This Wire brief sits within Fusion42's coverage of Biotech, and 3 sources have reported it between 8 Oct 2026 and 9 Oct 2026.
◆ ◆ The Wire takeaway
You need to prepare for faster regulatory timelines as FDA’s fast track on VIR-5500 signals growing acceptance of T-cell engagers in prostate cancer. Use this opening to engage with trial sites and future partners ahead of the 2027 phase 3 launch.
◆ Coverage
3 sources · first reported 8 Oct 2026 · latest 9 Oct 2026
◆ Related on Wire
◆ Topics